Viiv Healthcare

This study looked at two ways to control HIV in 171 adults who had never been treated before. Everyone started with a daily pill (dolutegravir/lamivudine). Once the virus was undetectable, participants could choose to switch to a shot (cabotegravir plus rilpivirine) given every t…

This study looked at whether adults aged 50 and older living with HIV could safely switch from a three-drug pill to a simpler two-drug pill (DTG/3TC) while keeping the virus under control. About 200 participants who already had undetectable virus levels made the switch and were f…

This study offers continued access to the HIV medication dolutegravir for children and teenagers who previously took part in related studies. About 100 participants who tolerated the drug well and still need it will receive age-appropriate doses every 12 weeks until the drug is l…

This early-stage study tested a new experimental HIV drug called VH4524184 in 84 healthy adults to see if it is safe and how the body processes it. The study also looked at whether the drug affects a key liver enzyme. Because HIV requires lifelong treatment, this is not a cure bu…

This study tested a once-daily pill containing two HIV drugs (dolutegravir and lamivudine) in 32 adolescents aged 12 to 17 who had never taken HIV medication before. The goal was to see if this simpler two-drug regimen could control the virus as well as standard three-drug combin…

This completed Phase 2a trial tested two experimental oral drugs, VH4004280 and VH4011499, in 44 adults with HIV who had never taken antiretroviral therapy. The goal was to see how well these capsid inhibitors could lower the amount of virus in the blood over 10 days. The study a…

This completed phase 4 study looked at how to best offer cabotegravir PrEP (a long-acting injection and tablets) to Black cisgender and transgender women in the US who do not have HIV. About 370 women took part, and researchers measured how well different delivery strategies work…

This completed study looked at how to best offer cabotegravir, an HIV prevention shot, in US clinics. About 287 men and transgender men at risk for HIV took part. Researchers compared two ways of rolling out the shot to see which worked better in busy and less busy clinics.

This study tested a more concentrated version of the long-acting HIV drug cabotegravir in 138 healthy adults. Researchers gave the injection in different ways (into muscle or under the skin) to see how the body processes it and to check for side effects. The goal was to gather sa…

This completed Phase 1 study tested an experimental HIV drug called VH4524184 in 126 healthy adults aged 18 to 60. The goal was to see how the drug is absorbed by the body, how it behaves when taken with food, and whether it interacts with other common medicines like metformin or…

This study tested two different long-acting versions of the HIV drug cabotegravir in 56 healthy adults. The goal was to see how safe they are and how the body processes them. No treatment was given for HIV; the study simply gathered information to help develop better formulations…